PREVENTION AND CONTROL OF DISEASE (USE OF VACCINES) REGULATION (Chapter 599 sub. leg. K)

It is hereby notified that, in exercise of the power conferred on the Secretary for Health by section 5(2) of the Prevention and Control of Disease (Use of Vaccines) Regulation (Cap. 599 sub. leg. K), the Secretary for Health extended the effective period of authorization of Comirnaty COVID-19 mRNA Vaccine (BNT162b2) Concentrate for Dispersion for Injection for 6 months to 24 July 2023. The conditions attached to the authorization, as set out under G.N. 395 of 2021, will continue to apply.